Elimination of Human Papillomavirus 16-Positive Tumors by a Mucosal rAd5 Therapeutic Vaccination in a Pre-Clinical Murine Study
Therapeutic vaccination can harness the body's cellular immune system to target and destroy cancerous cells. Several treatment options are available to eliminate pre-cancerous and cancerous lesions caused by human papillomaviruses (HPV), but may not result in a long-term cure. Therapeutic vaccination may offer an effective, durable, and minimally intrusive alternative. We developed mucosally delivered, recombinant, non-replicating human adenovirus type 5 (rAd5)-vectored vaccines that encode HPV16's oncogenic proteins E6 and E7 alongside a molecular dsRNA adjuvant. The induction of antigen-specific T cells and the therapeutic efficacy of rAd5 were evaluated in a mouse model of HPV tumorigenesis where E6E7-transformed cells, TC-1, were implanted subcutaneously in C57BL/6 mice. After tumor growth, mice were treated intranasally with rAd5 vaccines expressing the wildtype form of E6E7 (rAd5-16/E6E7<sub>Wt</sub>) in combination with an anti-PD-1 antibody or isotype control. Animals treated with rAd5-16/E6E7<sub>Wt</sub> with and without anti-PD-1 had significant reductions in tumor volume and increased survival compared to controls. Further, animals treated with rAd5-16/E6E7<sub>Wt</sub> had increased CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) and produced a cytotoxic tumor microenvironment. In a second study, the immunogenicity of a non-transformative form of E6E7 (rAd5-16/E6E7<sub>Mu</sub>) and a vaccine encoding predicted T cell epitopes of E6E7 (rAd5-16/E6E7<sub>epi</sub>) were evaluated. These vaccines elicited significant reductions in TC-1 tumor volume and increased survival of animals. Antigen-specific CD8+ T effector memory cells were observed in the animals treated with E6E7-encoding rAd5, but not in the rAd5-empty group. The work described here demonstrates that this mucosal vaccination can be used therapeutically to elicit specific cellular immunity and further identifies a clinical candidate with great potential for the treatment and prevention of human cervical cancer.
Authors
- Sean N. Tucker (ORCID: https://orcid.org/0000-0002-6233-225X)
- Jonathan D. Lindbloom
- Molly R. Braun (ORCID: https://orcid.org/0000-0002-7730-565X)
- Emery G. Dora (ORCID: https://orcid.org/0000-0002-0587-2751)
- Anne Moore (ORCID: https://orcid.org/0000-0003-3656-4230)
- Katherine A. Hodgson
Institutions
- University College Cork (IE)
- Vaxart (United States) (US)
- National Institute for Bioprocessing Research and Training (IE)
Publication Details
- Journal
- Vaccines
- Published
- 2024-08-23
- DOI
- https://doi.org/10.3390/vaccines12090955
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.24